ArticleACR open rheumatology2026
The Usefulness of White Blood Cell Inflammatory Parameters in Children With Systemic Lupus Erythematosus.
Article in ACR open rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTo evaluate the utility of novel parameters related to immune cell activation, known as white blood cell parameters of inflammation (WBC-IP), as biomarkers of disease activity in childhood-onset systemic lupus erythematosus (cSLE) and compare their performance with conventional markers, including erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and procalcitonin (PCT).
methodsWe conducted a cross-sectional analysis, including patients with cSLE with active disease (n = 43), remission (n = 31), and healthy controls (n = 112). In a separate longitudinal cohort, patients with active cSLE at baseline were reassessed after four to six weeks and when achieving inactive disease. WBC-IP was measured in dipotassium EDTA-anticoagulated tubes using the Sysmex XN-Series analyzer. Associations with SLEDAI-2K, clinical SLEDAI-2K, and physician global assessment (PGA) scores were assessed using Spearman's rank correlation. Diagnostic performance for distinguishing active disease from remission was evaluated by the area under the receiver operating characteristic curve (AUC).
resultsSignificant alterations in neutrophil- and lymphocyte-related parameters were observed across disease states. The proportion of immature granulocytes (IG%) correlated most strongly with the SLEDAI-2K (r
conclusionAmong the WBC-IP evaluated, IG% showed the strongest association with disease activity and demonstrated diagnostic performance comparable to that of ESR, suggesting it may represent a potential biomarker of disease activity. Further validation in independent cohorts is warranted.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.